CNR1 and metabolic syndrome: Some of these drugs, such as the peripherally restricted CB1R inverse agonist JD5037 and the CB1R antagonist AM6545 have been shown to reduce obesity, reverse leptin resistance and improve dyslipidemia, hepatic steatosis and insulin resistance in genetically and diet-induced obese mice [30,33,34,35].